International accreditation to products of the Cuban health system
High-impact clinical research in Cuba forms the basis of its health system, whose scientists and development capabilities have shown significant results for years.
An eloquent example is that by the creation of novel products, the collectives in their institutions and others, considered a stimulating model of interaction operation, they treasure nine gold medals from the World Intellectual Property Organization (WIPO), for their contributions in the field of technological innovation.
Experts in the field consider that the experience is exceptional for a Third World nation and also subjected to a widespread blockade of the United States, yet attaches paramount importance to the formation and development of human capital, according to specialists from the Cuban Industrial Property Office.
The first medal awarded to Cuba in 1989 was given to the Finlay Institute for the Meningococcal (Neisseria Meningitidis) vaccine in group B; and in 1999 was followed by PPG, a multi-purpose drug from the National Center for Scientific Research (CNIC).
Only one year later it was obtained by the Center for Chemical Bioactives of the Central University of Las Villas, Marta Abreu, for her Biocida, a product achieved from a derivative of sugar cane.
Two medals awarded in 2002, respectively, to the Centers of Molecular Immunology (CIM) and the National Agricultural Health (CENSA), the latter in the present province of Mayabeque.
The first developed a molecule capable of improving treatments in patients with tumors of epithelial origin; and the other a method for the preservation of raw milk without refrigeration, under the trade name Stabilak.
In 2006, the WIPO award was reached by the Center for Synthetic Antigen Studies at the University of Havana, in collaboration with that of Ottawa, for its Vaccine against Haemophilus Influenzae Type B.
Two achieved in 2007, the CNIC and CENSA, with their inventions of the rapid microbiological diagnosis equipment (DIRAMIC), and the pig lung surfactant (SURFACEN).
Another press in 2011 received the Center for Genetic Engineering and Biotechnology, for its drug Heberprot-P for comprehensive care for patients with diabetic foot ulcers, which substantially reduces the risk of lower limb amputation.
The last was delivered in 2015, when it was won by the invention entitled Monoclonal Antibody AntiCD6 for the treatment and diagnosis of psoriasis, from the Center for Molecular Immunology.
The Cuban Industrial Property Office is an institution of the Ministry of Science, Technology and Environment, responsible for the establishment of the legal regime, policy, management and management, as well as the provision of the corresponding services.
At the agency’s 2019 annual meeting, the entry into force for Cuba of the Protocol of Amendment to the Agreement on Trade-Related Industrial Property Aspects (TRIPS) of the World Trade Organization was announced.
The amendment provides legal certainty for exporting generic medicines at reasonable prices to meet the needs of countries that lack capabilities or are limited to produce pharmaceuticals.
More than 80 countries have been interested in acquiring the Recombinant Human Interferon 2b, obtained years ago at the Center for Genetic Engineering and Biotechnology, and which has proven its effectiveness in therapy of the new coronavirus.